CD274 and non-small cell lung carcinoma: In addition, immune checkpoint inhibitors (ICIs), especially anti-PD-1 or anti-PD-L1 antibodies (Abs), have recently been established as a novel treatment strategy and reported to improve the prognosis of patients with advanced and recurrent NSCLC [4,5,6,7].